Replies to post #212903 on Innovation Pharmaceuticals Inc (IPIX)

[Echo20]

Frrol

Those figures are close to miraculous!

Great post.

Echo20

[BIzzy]

“Radiation exposure protocol aside “ seems like the clinical trial equivalent of “ and how did you enjoy the play, Mrs Lincoln”....if your pool of trial applicants were exposed to a more targeted and thus more benign radiation it seems less miraculous...add in hours of IV administration and no data on PREVENTION....meh...B wins in a landslide

[PlentyParanoid]

Ffrol, Your find may change everything, or not.

Your tidbit uses term 'average' instead of median for durations. That would be the first. So far all other reported measures comparing OM durations have been using medians, which is, in my opinion, very misleading when the duration distributions are fat tailed as they tend to be with OM.

But, if GALERA is reporting real averages then...
The reduction reported would be immense if it is FROM AVERAGE of 19 days with placebo to AVERAGE of 1.5 days with GC4419.

But there might be a problem brewing...
I can't find the word average in any other report about GALERA's trial results.

Galera's site is currently inaccessible but Google cache shows no word average in the item on Galera's own site. See this:
"Phase 2b clinical trial demonstrate GC4419’s ability to dramatically reduce the duration of severe OM from 19 days to 1.5 days (92 percent)"

and the same in here.
It looks like your quote is the ONLY one using the word average as if the writer had decided to add some color into otherwise dry report.

Let's see how this will go:
If GALERA is REALLY reporting real changes in real averages then Leo has reasons to be worried, not desperate, but worried.
If the reported values turn out to be medians then it is the same old garbage, and not that much better garbage than what was reported for Kepivance